Pancreatic Cancer Research

ResearcherComprehensive Cancer Center ViennaActive in the last 2 years

Martin Schindl

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0941-2127; OpenAlex author ID A5045833996. Sources: OpenAlex.

Their work

Papers
21 (first author 1, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
46
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: none · 2014: 3 papers · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: 2 papers · 2020: 6 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 4 papers · 2025: 1 paper

Papers 21

  1. Prognostic factors for very early recurrence after neoadjuvant treatment and curative resection in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2025.109647↗
  2. Prognostic significance of mean corpuscular volume in patients with pancreatic ductal adenocarcinoma and multimodal treatment. Last author DOI 10.1016/j.jviscsurg.2023.06.004↗
  3. Immune cell distribution and DNA methylation signatures differ between tumor and stroma enriched compartment in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.trsl.2024.05.005↗
  4. Prognostic impact of resection margin status on survival after neoadjuvant treatment for pancreatic cancer: systematic review and meta-analysis. Co-author DOI 10.1097/js9.0000000000000792↗
  5. The Revised R Status is an Independent Predictor of Postresection Survival in Pancreatic Cancer After Neoadjuvant Treatment. Co-author DOI 10.1097/sla.0000000000005874↗
  6. Smoking impairs the effect of neoadjuvant FOLFIRINOX on postresection survival in pancreatic cancer. Co-author DOI 10.1016/j.ejca.2023.113293↗
  7. A GATA6-centred gene regulatory network involving HNFs and ΔNp63 controls plasticity and immune escape in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2020-321397↗
  8. [Surgery for periampullary pancreatic cancer]. Co-author DOI 10.1007/s00104-021-01462-1↗
  9. Systemic Immune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection. Last author DOI 10.1007/s11605-019-04187-z↗
  10. Applied precision medicine in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1177/1758835920938611↗
  11. The Prognostic Index Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Resection. Last author DOI 10.1245/s10434-019-08161-6↗
  12. Reply to Comments by Sun et al. on "The Prognostic Index Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Resection… Last author DOI 10.1245/s10434-020-08373-1↗
  13. Correction to: The Prognostic Index Independently Predicts Survival in Patients with Pancreatic Ductal Adenocarcinoma Undergoing Resection. Last author DOI 10.1245/s10434-020-09010-7↗
  14. Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients. Co-author DOI 10.3390/jcm9030648↗
  15. Objective and subjective comparison of virtual monoenergetic vs. polychromatic images in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00330-019-06116-9↗
  16. Sarcopenia and sarcopenic obesity are independent adverse prognostic factors in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0215915↗
  17. Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma. Co-author DOI 10.3978/j.issn.2078-6891.2015.107↗
  18. Preparing for prospective clinical trials: a national initiative of an excellence registry for consecutive pancreatic cancer resections. Co-author DOI 10.1007/s00268-013-2283-3↗
  19. Phosphorylation of STAT3 correlates with HER2 status, but not with survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/apm.12194↗
  20. A phase II trial of two durations of Bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer. First author PMID 24778046↗
  21. NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer. Co-author DOI 10.1007/s00268-011-1113-8↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Klaus Sahora · 14 shared papers, 2011–2025 · strength 1.81
  2. Gerald W. Prager · 7 shared papers, 2016–2025 · strength 1.08
  3. Elisabeth S. Gruber · 7 shared papers, 2019–2024 · strength 1.01
  4. Thomas P. Hank · 5 shared papers, 2021–2025 · strength 0.96
  5. Oliver Strobel · 5 shared papers, 2021–2025 · strength 0.96
  6. Gerd Jomrich · 6 shared papers, 2019–2024 · strength 0.88
  7. Carl-Stephan Leonhardt · 4 shared papers, 2023–2025 · strength 0.79
  8. Ulla Klaiber · 4 shared papers, 2021–2024 · strength 0.73
  9. Michael Gnant · 7 shared papers, 2011–2020 · strength 0.62
  10. Andrew Louis Warshaw · 3 shared papers, 2023–2025 · strength 0.57
  11. Motaz Qadan · 3 shared papers, 2023–2025 · strength 0.57
  12. Keith D. Lillemoe · 3 shared papers, 2023–2025 · strength 0.57
  13. Carlos F. Fernandez-del Castillo · 2 shared papers, 2023–2025 · strength 0.39
  14. Cristina Rosa Ferrone · 2 shared papers, 2023–2024 · strength 0.34
  15. Cristina R. Ferrone · 1 shared paper, 2025 · strength 0.23
  16. Caroline Sophie Verbeke · 1 shared paper, 2024 · strength 0.22
  17. Carlos Fernández-del Castillo · 1 shared paper, 2024 · strength 0.18
  18. Werner Scheithauer · 2 shared papers, 2016–2020 · strength 0.18
  19. Anna Sophie Berghoff · 1 shared paper, 2024 · strength 0.18
  20. Elisabeth Sophie Bergen · 1 shared paper, 2024 · strength 0.18
  21. Julia Maria Berger · 1 shared paper, 2024 · strength 0.18
  22. Erwin Tomasich · 1 shared paper, 2024 · strength 0.18
  23. Hossein Taghizadeh · 1 shared paper, 2020 · strength 0.15
  24. Ahmed Ba‐Ssalamah · 2 shared papers, 2014–2019 · strength 0.14
  25. Matthias Unseld · 1 shared paper, 2020 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.